Zhou Suna, Ye Wenguang, Zhang Mingxin, Liang Jun
Department of Radiotherapy, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Crit Rev Eukaryot Gene Expr. 2012;22(2):149-60. doi: 10.1615/critreveukargeneexpr.v22.i2.60.
To date, preclinical and clinical data have shown that various cancer patients benefit from antiangiogenic therapy because of the important role of angiogenesis in the tumor development process. NF-E2-related factor 2 (Nrf2) is recognized as a key transcription factor of genes coding for various antioxidant and cytoprotective enzymes, and Nrf2 plays important roles during tumor progression. Recent studies have begun to explore the role of Nrf2 in tumor angiogenesis, which may be to promote the advancement of tumor antiangiogenic therapy. This article reviews the Nrf2-related pathways involved in tumor angiogenesis and summarizes the possible mechanisms of Nrf2 action as a pro-angiogenic factor in tumor progression.
迄今为止，临床前和临床数据表明，由于血管生成在肿瘤发展过程中的重要作用，各种癌症患者都能从抗血管生成治疗中获益。核因子E2相关因子2（Nrf2）被认为是编码各种抗氧化和细胞保护酶的基因的关键转录因子，并且Nrf2在肿瘤进展过程中发挥重要作用。最近的研究开始探索Nrf2在肿瘤血管生成中的作用，这可能会推动肿瘤抗血管生成治疗的进展。本文综述了参与肿瘤血管生成的Nrf2相关途径，并总结了Nrf2作为肿瘤进展中促血管生成因子的可能作用机制。
